Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 12 , ISSUE 1 ( January-February, 2020 ) > List of Articles

Original Article

Surgical and Survival Outcomes with Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Longitudinal Study in a Tertiary Cancer Center

Rekha B Raghavendrachar, Rani A Bhat, Vibhawari Dhakaria

Citation Information : Raghavendrachar RB, Bhat RA, Dhakaria V. Surgical and Survival Outcomes with Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Longitudinal Study in a Tertiary Cancer Center. J South Asian Feder Obs Gynae 2020; 12 (1):27-30.

DOI: 10.5005/jp-journals-10006-1751

License: CC BY-NC 4.0

Published Online: 02-11-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Aims: To evaluate surgical and survival outcomes following neoadjuvant chemotherapy followed by interval debulking surgery (IDS) in advanced epithelial ovarian cancer (AEOCs). Materials and methods: Fifty patients who were diagnosed with stage III–IV ovarian cancer/primary peritoneal cancer/fallopian tube cancer were followed up following three cycles of neoadjuvant chemotherapy and debulking surgery followed by adjuvant chemotherapy in a comprehensive cancer center. This longitudinal study was conducted over four years from 2013–2017. Primary outcome measured was progression-free survival and secondary outcomes that included overall survival and effect of optimal and suboptimal surgeries on survival outcomes. In this study, we compared the difference in survival outcomes following various types of debulking (complete vs optimal vs suboptimal). Results: Among 50 patients who underwent debulking, 78%, 8%, and 14% underwent complete, optimal, and suboptimal debulking, respectively. The mean estimate of progression-free survival (PFS) at 24 months was 20.324 ± 0.97 months (95% CI) and the overall survival was 21.234 ± 0.788 months. There was a significant increase in PFS in those who had complete debulking (21.47 ± 0.95 months, 95% CI 19.6 to 23.3 months) compared to those in optimal debulking (20.53 months) and suboptimal groups (10.3 months) (Log-rank Mantel–Cox = 12.01, p = 0.001). Seventy-eight percent had no postoperative complications while 16% had grade I complications. Grade II, IV, and V complications were 2% each. Conclusion: Neoadjuvant chemotherapy followed by IDS gives better chance of complete debulking and better survival outcomes with acceptable postoperative complications.

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492.
  2. National Cancer Registry Program. Incidence, Distribution, Trends in Incidence Rates and Projections of Burden of Cancer. March 2016. pp. 43–62.
  3. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 2009;115(6):1234–1244. DOI: 10.1002/cncr.24149.
  4. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015;386(9990):249–257. DOI: 10.1016/S0140-6736(14)62223-6.
  5. Strong VE, Selby LV, Sovel M, et al. Development and assessment of memorial sloan kettering cancer center's surgical secondary events grading system. Ann Surg Oncol 2015;22(4):1061–1067. DOI: 10.1245/s10434-014-4141-4.
  6. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (Version 1.1). Eur J Cancer 2009;45(2):228–247. DOI: 10.1016/j.ejca.2008.10.026.
  7. Bland JM, Altman DG. The logrank test. BMJ 2004;328(7447):1073. DOI: 10.1136/bmj.328.7447.1073.
  8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 2.2019. Accessed September 17, 2019.
  9. Deo SVS, Hemant G, Shukla NK, et al. Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer. Indian J Cancer 2006;43(3):117–121. DOI: 10.4103/0019-509x.27933.
  10. Sonia B, Himanshu N, Dave Kalpna, et al. Role of neoadjuvant chemotherapy (NACT) followed by surgical cytoreduction in advanced epithelial ovarian cancer. The J Obstet Gynecol India 2012;62(5):541–545. DOI: 10.1007/s13224-011-0106-8.
  11. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363(10):943–953. DOI: 10.1056/NEJMoa0908806.
  12. Baruah U, Barmon D, Kataki A, et al. Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study. Indian J Med Paediat Oncol 2015;36(1):38–42. DOI: 10.4103/0971-5851. 151781.
  13. Georgeena P, Rajanbabu A, Vijaykumar D, et al. Surgical treatment pattern and outcomes in epithelial ovarian cancer patients from a cancer institute in Kerala, India. Ecancermedicalscience 2016;10:619. DOI: 10.3332/ecancer.2016.619.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.